Elsevier

Metabolism

Volume 43, Issue 3, March 1994, Pages 348-356
Metabolism

Phenobarbital treatment enhances insulin-mediated glucose metabolism and improves lipid metabolism in the diabetic rat

https://doi.org/10.1016/0026-0495(94)90103-1Get rights and content

Abstract

Previous studies with healthy volunteers and non-insulin-dependent diabetic (NIDDM) patients have shown a strong association between overall glucose metabolism and hepatic microsomal enzyme activity. In this study, the effects of 10-day oral administration of phenobarbital (PB), a potent inducer of the hepatic microsomal mixed-function oxidase system, on carbohydrate and lipid metabolism in the basal state and on glucose kinetics during submaximal hyperinsulinemic (5 mU · kg−1 · min−1 insulin) clamps were investigated in nondiabetic rats and in rats made diabetic by the intravenous (IV) administration of either low-dose (40 mg/kg) or high-dose (55 mg/kg) streptozocin (STZ). In control rats receiving PB in drinking water (0.5 mg/mL), serum insulin and triglyceride levels were diminished without any change in glucose and cholesterol concentrations in the fed state. Administration of PB in drinking water (0.25 mg/mL) to both groups of diabetic rats decreased their water intake and serum triglyceride levels in the absence of an effect on glucose, insulin, and cholesterol concentrations in the fed state. However, fasting serum glucose levels and basal glucose turnover rates were lower in both groups of diabetic rats receiving PB. PB treatment increased the heparin-releasable lipoprotein lipase (LPL) activity of epididymal fat in both control and low-dose diabetic groups; this was not assessed in the high-dose diabetic group. Neither peripheral glucose utilization nor hepatic glucose production during submaximal insulin clamps was modified by PB treatment in nondiabetic rats. In contrast, PB administration enhanced insulin-mediated peripheral glucose utilization, as well as suppression of hepatic glucose production, in both low-dose and high-dose diabetic groups. The stimulatory effect of PB on insulin-mediated glucose utilization in low-dose diabetic rats was confirmed by increased incorporation of (3-3H)glucose into glycogen in the rectus muscle measured at the end of the clamp. In conclusion, (1) PB administration decreased fasting serum glucose levels and augmented insulin-mediated glucose metabolism in insulin-deficient diabetic rats, and (2) the triglyceride-lowering effect of PB in both nondiabetic and diabetic rats may be in part due to increased clearance by adipose tissue LPL.

References (52)

  • FC Kauffman et al.

    Alterations in nicotinamide and adenine nucleotide systems during mixed-function oxidation of p-nitroanisole in perfused livers from normal and phenobarbital-treated rats

    Biochem J

    (1977)
  • I Karvonen et al.

    Effects of enzyme induction therapy on glucose and drug metabolism in obese mice model of non-insulin dependent diabetes mellitus

    Diabetes Res

    (1989)
  • JT Lahtela et al.

    Phenobarbital treatment enhances insulin mediated glucose metabolism in man

    Res Commun Chem Pathol Pharmacol

    (1984)
  • JT Lahtela et al.

    The effect of liver microsomal enzyme inducing and inhibiting drugs on insulin mediated glucose metabolism in man

    Br J Clin Pharmacol

    (1986)
  • JT Lahtela et al.

    Enzyme inducers improve insulin sensitivity in non-insulin-dependent diabetic subjects

    Diabetes

    (1985)
  • DM Goldberg et al.

    Triacylglycerol metabolism in the phenobarbital-treated rat

    Biochem J

    (1981)
  • I Karvonen et al.

    Hepatic mixed function oxidase system and enzymatic glucose metabolism in rats

    Diabetes Res

    (1987)
  • N Venkatesan et al.

    Antidiabetic action of vanadyl in rats independent of in-vivo insulin-receptor kinase activity

    Diabetes

    (1991)
  • TW Jones et al.

    Independent effects of youth and poor diabetes control on responses to hypoglycemia in children

    Diabetes

    (1991)
  • DC Deibert et al.

    Epinephrine-induced insulin resistance in man

    J Clin Invest

    (1980)
  • DT Finegood et al.

    Estimation of endogenous glucose production during hyperinsulinemic-euglycemic glucose clamps. Comparison of unlabeled and labeled exogenous glucose infusates

    Diabetes

    (1987)
  • DT Finegood et al.

    Modeling error and apparent isotope discrimination confound estimation of endogenous glucose production during euglycemic glucose clamps

    Diabetes

    (1988)
  • JM Molina et al.

    Use of a variable tracer infusion method to determine glucose turnover in humans

    Am J Physiol

    (1990)
  • JR Allsop et al.

    The reliability of rates of glucose appearance in vivo calculated from constant tracer infusions

    Biochem J

    (1978)
  • TB Issekutz et al.

    Estimation of hepatic glucose output in non-steady state. The simultaneous use of 2-3H-glucose and 14C-glucose in the dog

    Can J Physiol Pharmacol

    (1974)
  • RR Wolfe
  • Cited by (19)

    • Evodia alkaloids suppress gluconeogenesis and lipogenesis by activating the constitutive androstane receptor

      2016, Biochimica et Biophysica Acta - Gene Regulatory Mechanisms
      Citation Excerpt :

      Increasing evidence suggests that CAR also has an endobiotic function in regulating the glucose and lipid metabolism, making it a potential therapeutic target to manage metabolic disease [14–16]. Activation of CAR by phenobarbital (PB) suppresses the expression of hepatic gluconeogenic genes and hepatic glucose production in both normal and diabetes mouse models [15,17–19]. Forkhead box O1 (FoxO1) and hepatocyte nuclear factor 4α (HNF4α) function as two positive regulators of gluconeogenesis by transactivating the PEPCK and G6Pase gene promoters [20,21].

    • Phenobarbital reduces blood glucose and gluconeogenesis through down-regulation of phosphoenolpyruvate carboxykinase (GTP) gene expression in rats

      2015, Biochemical and Biophysical Research Communications
      Citation Excerpt :

      PB suppressed PEPCK gene expression would be responsible for the reduction of blood glucose. Venkatesan et al. showed that glucose production was suppressed in PB-treated diabetic rats in the insulin clamp test [21]. Because pyruvate-induced increase in blood glucose is abolished by administration of an inhibitor of PEPCK [22,23], we used pyruvate challenge test to examine the gluconeogenic activity in this study.

    • The constitutive androstane receptor is an anti-obesity nuclear receptor that improves in sulin sensitivity

      2009, Journal of Biological Chemistry
      Citation Excerpt :

      It is tempting for us to propose that CAR may represent a novel therapeutic target to manage obesity and type 2 diabetes. Indeed, the CAR agonist phenobarbital has been shown to enhance insulin sensitivity and improve glucose and lipid metabolism in diabetic rats (36) and in diabetic patients (37, 38). Obesity is a medical problem of high prevalence.

    • PXR and CAR in energy metabolism

      2009, Trends in Endocrinology and Metabolism
      Citation Excerpt :

      Given the fact that CAR inhibits gluconeogenesis and lipogenesis, an outstanding question is whether CAR activation offers therapeutic benefits in obese and diabetic patients, who often suffer from both hyperglycemia and hyperlipidemia. Indeed, the CAR agonist phenobarbital has been shown to enhance insulin sensitivity and improve glucose and lipid metabolism in diabetic rats [52] and in diabetic patients [53,54]. Recent findings from many laboratories have clearly suggested that PXR and CAR regulate not only drug metabolism but also energy homeostasis.

    View all citing articles on Scopus

    Supported in part by a grant-in-aid (946 GI-1) from the American Heart Association, Greater Los Angeles Affiliate, Inc, and by US Public Health Service Grant No. DK-39176.

    View full text